Payer status, but not race, affects the cost of liver transplantation

Mark W. Russo, Robert S. Sandler, Lawrence Mandelkehr, Jeffrey H. Fair, Mark W. Johnson, Robert S Brown – 30 December 2003 – Prior studies evaluating the impact of race and payer on cost of liver transplantation did not adjust for clinical factors known to increase cost. We analyzed the impact of race and payer on the cost of liver transplantation after controlling for clinical factors.

Percutaneous mesenteric venous thrombectomy and thrombolysis: Successful treatment followed by liver transplantation

Robert Ryu, Terry C. Lin, David Kumpe, Joseph Krysl, Janette D. Durham, James S. Goff, Gregory T. Everson, Igal Kam, Michael Wachs, Paul Russ, Roshan Shrestha, Thomas E. Trouillot, Bahri M. Bilir, – 30 December 2003 – Mesenteric vein thrombosis (MVT) is a rare cause of intestinal ischemia. Because of its nonspecific symptoms, diagnosis is often delayed. We describe a patient with liver cirrhosis who developed acute MVT while waiting for liver transplantation. Surgical intervention carried a high risk because of her underlying cirrhosis.

Natural history of liver disease in cystic fibrosis

Anders Lindblad, Hans Glaumann, Birgitta Strandvik – 30 December 2003 – The median age of the population with cystic fibrosis (CF) has increased worldwide, which has led to the suggestion that the prevalence of liver disease would increase. The aim of this study was to evaluate the natural history of CF‐associated liver disease over a 15‐year period in a well‐controlled population of patients with CF. During the years 1976 through 1993, 124 patients were followed up by yearly liver function tests (LFTs).

Outcome ofDe Novohepatitis C virus infection in heart transplant recipients

Janus P. Ong, David S. Barnes, Zobair M. Younossi, Terry Gramlich, Belinda Yen‐Lieberman, Marlene Goormastic, Cedric Sheffield, Kathy Hoercher, Randall Starling, James Young, Nicholas Smedira, Patrick McCarthy – 30 December 2003 – The outcome ofde novohepatitis C virus (HCV) infection in heart transplant recipients of HCV‐antibody positive organs is not known. The aim of the study was to determine the short‐term outcome of de novoHCV infection in recipients of HCV‐positive donor organs.

KDR/Flk‐1 is a major regulator of vascular endothelial growth factor–induced tumor development and angiogenesis in murine hepatocellular carcinoma cells

Hitoshi Yoshiji, Shigeki Kuriyama, Daniel J. Hicklin, James Huber, Junichi Yoshii, Yoji Miyamoto, Mitsuhiro Kawata, Yasuhide Ikenaka, Toshiya Nakatani, Hirohisa Tsujinoue, Hiroshi Fukui – 30 December 2003 – Vascular endothelial growth factor (VEGF), which is one of the most potent angiogenic factors, has been shown to play a pivotal role in tumor angiogenesis, including hepatocellular carcinoma (HCC). The effects of VEGF are mediated mainly through two distinct receptors, flt‐1 and KDR/Flk‐1. It has been suggested that KDR/Flk‐1 plays an important role in tumor development.

Decreased p27Kip1 expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with resectable extrahepatic bile duct carcinoma

Ai‐Min Hui, Xing Cui, Masatoshi Makuuchi, Xin Li, Ya‐Zhou Shi, Tadatoshi Takayama – 30 December 2003 – This study was undertaken to identify potential abnormalities of p27Kip1 and cyclin D1 expression in extrahepatic bile duct carcinomas and to assess the prognostic significance of p27Kip1 and cyclin D1 levels for patients with this disease. Decreased p27Kip1 expression (<50% nuclei staining) and cyclin D1 overexpression (>5% nuclei staining) was observed immunohistochemically in 19 (56%) and 23 (68%) of the 34 tumors examined, respectively.

Differential regulation of extracellular matrix synthesis during liver regeneration after partial hepatectomy in rats

K. Lenhard Rudolph, Christian Trautwein, Stefan Kubicka, Tim Rakemann, Matthias J. Bahr, Nick Sedlaczek, Detlef Schuppan, Michael P. Manns – 30 December 2003 – Little is known about the modulation of the extracellular matrix (ECM) during liver regeneration. We studied the temporospatial expression of procollagens and of matrix metalloproteinases (MMPs) and their physiological antagonists, the tissue inhibitors of metalloproteinases (TIMPs) after two‐thirds partial hepatectomy (PH) by Northern blot analysis and in situ hybridization.

Subscribe to